SCHEMBL10247600

SCHEMBL10247600

c1cn(CCCCCCCCCCCCn2ccnc2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 14/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29004413 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL937530 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL29004411 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL2532389 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL939851 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL1679410 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL285054 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL2533366 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL2535103 1.00 TBXAS1 (1.00) TBXAS1
SCHEMBL2531537 1.00 TBXAS1 (1.00) TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190169342-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA, INC. 2019-06-06 US disclosed
EP-3130343-B1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA INC (US) 2018-05-09 EP disclosed
EP-3130343-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS Relypsa, Inc. (US) 2017-02-15 EP disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-20130189215-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA, INC. (US) 2013-07-25 US disclosed
US-20130189215-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA, INC. (US) 2013-07-25 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
WO-2011106545-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA, INC. (US) 2011-09-01 WO disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System TXNRD2, HMOX1, HMOX2 TBXAS1 469/4885
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 TBXAS1 1071/4885
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 TBXAS1 1071/4885
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 TBXAS1 1257/4885
US-20130189215-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS NR1H4, SLC10A2, ITCH TBXAS1 2184/4885
US-20190169342-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS NR1H4, SLC10A2, ITCH TBXAS1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.